PANBioRA will provide a set of tools, composed of protocols and instruments standardising the evaluation of new biomaterials for aspects such as cyto and genotoxicity. In addition, the project will generate a validated, general methodology to characterise biomaterials.
17 EU partners developing a platform to optimise engineered biomaterials for ATMP and Medical devices. H2020 GA number 760921, Total funding: 7.9 Million Euros.
Research Topic for PANBioRA “Adverse Reactions to Biomaterials: State of the Art in Biomaterial Risk Assessment, Immunomodulation and In Vitro Models for Biomaterial Testing” in Frontiers in Bioengineering and Biotechnology (2017): https://www.frontiersin.org/research-topics/6661/adverse-reactions-to-biomaterials-state-of-the-art-in-biomaterial-risk-assessment-immunomodulation-a